Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

Our Products
Overview
Partnering Search
Company Profiling
Partneringtools
Reports
Partnering Consulting
Comparison
 
Forums
Visit our forums
 
Jobs
Visit our job site
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire New!
 
Contact us
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing Ltd
is a division of
UTEK Corporation
Out-licensing

Up-to-date access to technology licensing opportunities worldwide.

Licensing opportunities

Displaying 1..10 of 23 - per page Next page
Order by
We are seeking to out-license our innovative Soluleaves range More
Cellophil (TM) is particularly designed for optical lenses, drug delivery and also may be used as additive for food and cosmetics or as fiber for fabrics. More
MT204, in preclinical development stage, neutralizes both IL-2 as well as IL-2 bound to CD25 conferring a broader anti-inflammatory activity over current therapies targeting IL-2 pathway for the treatment of inflammatory and autoimmune diseases. More
Patented technology regarding new and safe mechanism with the active substance PH3 for the indications of osteoporosis and diabetic vascular complications. More
A Robarts' Scientist has generated a target-based primary in vitro cell-based screen for evaluating compounds or peptides affecting scar matrix deposition and remodeling during wound repair. More
This ophthalmic solution provides relief of the symptoms associated with dry eye, improving the quality of life among sufferers in both mild-moderate and chronic dry eye cases. More
K-115 is a small molecule, new chemical compound that selectively inhibits Rho kinase. Kowa is developing K-115 in Japan as an ophthalmic solution for the treatment of glaucoma. More
iGen™ is a collagen implant, and is a biodegradable scaffold which can induce a regenerative non-scarring wound healing process without the use of medicine. The ophthalmology applications for iGen™ include glaucoma, pterygium, ocular tissue, and More
SmarBUCKL is produced with biocompatible and slow-resorbing biomaterials which will not induce immunoreactions and can be resorbed after implantation. The SmarBUCKL doesn't need to be exteriorized by a second operation after patient recovers. More
Novel library of synthetic NGF agonists that bind in a highly specific manner the tropomyosin kinases (Trk) receptor. More
Displaying 1..10 of 23 - per page Next page
Order by
Partnering consultation free of charge
Biomarkers for sepsis and infectious diseases
Maximizing Pharmaceutical Patent Lifecycles
Industry news: Pharmalicensing provides comprehensive industry coverage.

© Copyright 1995-2008 Pharmalicensing Ltd, is a division of UTEK Corporation All rights reserved. Terms and Conditions | Site map | Contact us